Suppr超能文献

在常规医院诊疗中,患者抗Jo-1抗体呈阳性意味着什么?一项回顾性巢式病例对照研究。

What does it mean if a patient is positive for anti-Jo-1 in routine hospital practice? A retrospective nested case-control study.

作者信息

Jobanputra Paresh, Malick Feryal, Derrett-Smith Emma, Plant Tim, Richter Alex

机构信息

Department of Rheumatology, Queen Elizabeth Hospital, Birmingham, Birmingham, B15 2TH, UK.

Department of Rheumatology, Epsom and St Helier University Hospitals NHS Trust, Carshalton, Surrey, SM15 1AA, UK.

出版信息

F1000Res. 2018 Jun 4;7:698. doi: 10.12688/f1000research.14834.1. eCollection 2018.

Abstract

It is widely believed that patients bearing auto-antibodies to histidyl tRNA synthetase (anti-Jo-1) very likely have a connective tissue disease including myositis and interstitial lung disease.  The value of positive tests in low disease prevalence settings such as those tested in routine care is unknown.  We sought to determine the value of anti-Jo-1 auto-antibodies in routine practice. : Our study was a nested case control study within a retrospective cohort of all patients tested for anti-ENA our hospital, from any hospital department, between January 2013 and December 2014.  Data was extracted from electronic records of anti-Jo-1 positive patients and randomly selected ENA negative patients (ratio of 1:2), allowing for a minimum follow up of at least 12 months after first testing. 4009 samples (3581 patients) were tested.  Anti-ENA was positive in 616 (17.2%) patients, 40 (1.1%) were anti-Jo-1 positive. Repeat ENA testing was done for 350/3581 (9.8%) patients (428 of 4009 (10.7%) samples) and in 7/40 (17.5%) of anti-Jo-1 positive patients. The median interval between the first and second request was 124 days (inter-quartile range 233 days).  The frequencies of interstitial lung disease (ILD), myositis and Raynaud's were comparable for anti-Jo-1 positive patients (n=40) and 80 randomly selected ENA negative controls.  Positive tests led to additional diagnostic testing in the absence of clinical disease.  Sensitivity of Jo-1 for ILD was 50% (CI 19-81%), specificity 68% (CI 59-77%), positive predictive value 12.5% (CI 4 to 27%) and negative predictive value 93.8% (CI 86-98%). Of 10 (25%) patients with high anti-Jo1 levels, 3 had ILD, one myositis and two a malignancy (disseminated melanoma and CML).  Anti-Jo-1 is uncommon in a heterogenous hospital population and is only weakly predictive for ILD.  Repeated test requests were common and potentially unnecessary indicating that controls over repeat requests could yield significant cost savings.

摘要

人们普遍认为,携带组氨酰tRNA合成酶自身抗体(抗Jo-1)的患者很可能患有包括肌炎和间质性肺病在内的结缔组织疾病。在疾病患病率较低的情况下(如在常规护理中检测的那些情况),阳性检测的价值尚不清楚。我们试图确定抗Jo-1自身抗体在常规实践中的价值。我们的研究是一项巢式病例对照研究,纳入了2013年1月至2014年12月期间在我院接受抗可提取核抗原(ENA)检测的所有患者的回顾性队列,这些患者来自医院的任何科室。数据从抗Jo-1阳性患者的电子记录和随机选择的ENA阴性患者(比例为1:2)中提取,首次检测后至少随访12个月。共检测了4009份样本(3581名患者)。616名(17.2%)患者的抗ENA呈阳性,40名(1.1%)患者的抗Jo-1呈阳性。对350/3581名(9.8%)患者(4009份样本中的428份(10.7%))进行了重复ENA检测,抗Jo-1阳性患者中有7/40(17.5%)进行了重复检测。首次和第二次检测请求之间的中位间隔为124天(四分位间距为233天)。抗Jo-1阳性患者(n = 40)和80名随机选择的ENA阴性对照患者的间质性肺病(ILD)、肌炎和雷诺现象的发生率相当。在没有临床疾病的情况下,阳性检测导致了额外的诊断检测。Jo-1对ILD的敏感性为50%(可信区间19 - 81%),特异性为68%(可信区间59 - 77%),阳性预测值为12.5%(可信区间4至27%),阴性预测值为93.8%(可信区间86 - 98%)。在10名(25%)抗Jo1水平高的患者中,3名患有ILD,1名患有肌炎,2名患有恶性肿瘤(播散性黑色素瘤和慢性粒细胞白血病)。抗Jo-1在异质性医院人群中并不常见,对ILD的预测能力较弱。重复检测请求很常见且可能不必要,这表明对重复请求进行控制可以显著节省成本。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0faa/6058461/3808d301fd2f/f1000research-7-16147-g0000.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验